CURE ETF – Rallies 10%

ETFS S&P Biotech has been an overweight portfolio allocation and either taking profit now or sticking with the position, whilst the price action remains above the 10-day average, will provide a positive outcome.

The added buying interest in the US biotech sector following the recent announcement from Biogen is helping propel the CURE ETF.

You’re not a member!  Trial today

Ready to elevate your investing?

Join Investor Signals today and start your journey to better, more disciplined returns.